Valuation: Algorae Pharmaceuticals Limited

Market Cap 20.26M 14.3M 12.39M 11.6M 10.59M 19.92M 1.36B 136M 53.3M 683M 53.7M 52.53M 2.28B P/E 2024
-7.7x
P/E 2025 -10x
Enterprise Value 17.94M 12.66M 10.97M 10.27M 9.37M 17.64M 1.21B 120M 47.2M 605M 47.55M 46.51M 2.02B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
80.31%
Yield 2024 *
-
Yield 2025 -
1 month-7.69%
3 months-7.69%
6 months-45.45%
Current year-14.29%
1 week 0.01
Extreme 0.011
0.01
1 month 0.01
Extreme 0.011
0.01
Current year 0.01
Extreme 0.01
0.02
1 year 0.01
Extreme 0.006
0.02
3 years 0
Extreme 0.005
0.02
5 years 0
Extreme 0.003999
0.02
10 years 0
Extreme 0.003999
0.28
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 18/06/2023
Corporate Secretary - 30/06/2026
Corporate Secretary - 30/06/2026
Director TitleAgeSince
Chairman 52 04/01/2023
Director/Board Member - 09/03/2026
Director/Board Member 52 13/07/2026
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+100.00%-20.00% 17.17M
-0.70%+24.68%+76.72%+103.05% 70.85B
-2.35%+2.88%+35.39%+64.72% 55.41B
-1.95%+34.13%+17.33%+490.53% 29.43B
-0.30%+18.51%+56.61%+4.86% 24.12B
+0.03%+1.42%-15.20%-13.35% 23.31B
+0.05%+6.12%+46.81%-21.81% 18.37B
+9.77%+25.32%+252.40%+442.16% 16.99B
0.00%+10.84%+31.14%+628.97% 16.1B
-2.89%-8.09%+37.58%+139.17% 13.12B
Average +0.17%+351.64%+63.88%+181.83% 26.77B
Weighted average by Cap. -0.42%+349.14%+56.26%+165.07%

Financials

2024 2025
Net sales - -
Net income -2.1M -1.48M -1.28M -1.2M -1.1M -2.06M -141M -14.07M -5.51M -70.63M -5.56M -5.43M -236M -803K -567K -491K -460K -420K -790K -54.07M -5.39M -2.11M -27.06M -2.13M -2.08M -90.29M
Net Debt -3.11M -2.19M -1.9M -1.78M -1.62M -3.06M -209M -20.88M -8.18M -105M -8.24M -8.06M -350M -2.32M -1.64M -1.42M -1.33M -1.21M -2.28M -156M -15.58M -6.1M -78.17M -6.15M -6.01M -261M
Logo Algorae Pharmaceuticals Limited
Algorae Pharmaceuticals Limited is an Australia-based artificial-intelligence (AI) enabled pharmaceutical development company. The Company’s proprietary AI platform, Algorae Operating System (AlgoraeOS), is an AI platform that leverages extensive medical and scientific databases from various disciplines within an advanced system at the intersection of AI and pharmaceutical research. Its other drug candidates include AI-116, AI-168, NTCELL. AI-116 is a combination drug candidate made up of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease. AI-168 is a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient, which is conceptualized to be a potential treatment for cardiovascular disease, including hypertension. NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells.
Employees
48
Date Price Change Volume
11/08/26 A$0.0120 0.00% 804,087
10/08/26 A$0.0120 +9.09% 291,425
06/08/26 A$0.0110 -8.33% 669,985
05/08/26 A$0.0120 0.00% 11,428